{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:44:38Z","timestamp":1792421078902,"version":"4.5.0"},"reference-count":302,"publisher":"Harborside Press, LLC","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>There is an increased risk of infection in patients with cancer that results in higher morbidity and mortality. Several risk factors can predispose these patients to infectious complications. Some such factors include immunocompromised states like neutropenia, allogeneic hematopoietic cell transplantation, and graft-versus-host disease, while others include immunosuppressive agents like corticosteroids, purine analogs, monoclonal antibodies, and other emerging cancer therapeutics like CAR T-cell therapy. The NCCN Guidelines for the Prevention and Treatment of Cancer-Related Infections address infection concerns that may be observed in these immunocompromised populations and characterize the major pathogens to which patients with cancer are susceptible, with a focus on the prevention, diagnosis, and treatment of major common and opportunistic infections. This paper highlights 2 recently updated sections of the guidelines, namely, infection concerns related to CAR T-cell therapy and antimicrobial prophylaxis recommendations, including vaccination, in patients at high-risk for infections.<\/jats:p>","DOI":"10.6004\/jnccn.2024.0056","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T08:34:31Z","timestamp":1731486871000},"page":"617-644","source":"Crossref","is-referenced-by-count":88,"title":["Prevention and Treatment of Cancer-Related Infections, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology"],"prefix":"10.6004","volume":"22","author":[{"given":"Lindsey Robert","family":"Baden","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankar","family":"Swaminathan","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos G.","family":"Almyroudis","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Angarone","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliyah","family":"Baluch","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Barros","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Buss","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Cohen","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Cooper","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto Dulanto","family":"Chiang","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab El","family":"Boghdadly","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Gregg","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Hakim","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Ho","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fareed","family":"Khawaja","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Lee","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lee","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Logan","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Manley","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashrit","family":"Multani","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam","family":"Pande","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Pergam","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Pisano","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Saullo","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Schuster","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Seo","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shmuel","family":"Shoham","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy","family":"Taplitz","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Topal","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zimmer","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffet Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly J.","family":"Cassara","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kumar","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeenat","family":"Diwan","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Transpl Infect Dis","first-page":"e14157","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri E","year":"2023","unstructured":"Kampouri E, Little JS, Rejeski K,  Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies. Transpl Infect Dis 2023;25(Suppl 1):e14157."},{"key":"B2","series-title":"Transplant Cell Ther","first-page":"955","article-title":"Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid Z","year":"2024","unstructured":"Shahid Z, Jain T, Dioverti V,  Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies. Transplant Cell Ther 2024;30:955\u2013969."},{"key":"B3","series-title":"Ann Oncol","first-page":"259","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden PJ","year":"2022","unstructured":"Hayden PJ, Roddie C, Bader P,  Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol 2022;33:259\u2013275."},{"key":"B4","series-title":"Clin Microbiol Infect","first-page":"1280","article-title":"Predicting infections in patients with haematological malignancies treated with chimeric antigen receptor T-cell therapies: a systematic scoping review and narrative synthesis","volume":"29","author":"Reynolds G","year":"2023","unstructured":"Reynolds G, Sim B, Anderson MA,  Predicting infections in patients with haematological malignancies treated with chimeric antigen receptor T-cell therapies: a systematic scoping review and narrative synthesis. Clin Microbiol Infect 2023;29:1280\u20131288."},{"key":"B5","series-title":"N Engl J Med","first-page":"977","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","author":"Bucaneve G","year":"2005","unstructured":"Bucaneve G, Micozzi A, Menichetti F,  Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977\u2013987."},{"key":"B6","series-title":"N Engl J Med","first-page":"988","article-title":"Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas","volume":"353","author":"Cullen M","year":"2005","unstructured":"Cullen M, Steven N, Billingham L,  Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005;353:988\u2013998."},{"key":"B7","series-title":"Am J Hematol","first-page":"863","article-title":"Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial","volume":"85","author":"Eleutherakis-Papaiakovou E","year":"2010","unstructured":"Eleutherakis-Papaiakovou E, Kostis E, Migkou M,  Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial. Am J Hematol 2010;85:863\u2013867."},{"key":"B8","series-title":"Clin Infect Dis","first-page":"e56","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld AG","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA,  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:e56\u201393."},{"key":"B9","series-title":"Cochrane Database Syst Rev","first-page":"CD004386","article-title":"Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy","volume":"1","author":"Gafter-Gvili A","year":"2012","unstructured":"Gafter-Gvili A, Fraser A, Paul M,  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2012;1:CD004386."},{"key":"B10","series-title":"J Antimicrob Chemother","first-page":"5","article-title":"Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis","volume":"59","author":"Gafter-Gvili A","year":"2007","unstructured":"Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 2007;59:5\u201322."},{"key":"B11","series-title":"Clin Infect Dis","first-page":"1819","article-title":"Antimicrobial resistance in gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: intercontinental prospective study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group","volume":"65","author":"Averbuch D","year":"2017","unstructured":"Averbuch D, Tridello G, Hoek J,  Antimicrobial resistance in gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: intercontinental prospective study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group. Clin Infect Dis 2017;65:1819\u20131828."},{"key":"B12","series-title":"J Infect","first-page":"20","article-title":"Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines","volume":"76","author":"Mikulska M","year":"2018","unstructured":"Mikulska M, Averbuch D, Tissot F,  Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect 2018;76:20\u201337."},{"key":"B13","series-title":"J Clin Oncol","first-page":"4821","article-title":"Rational selection of patients for antibacterial prophylaxis after chemotherapy","volume":"25","author":"Cullen MH","year":"2007","unstructured":"Cullen MH, Billingham LJ, Gaunt CH, Steven NM. Rational selection of patients for antibacterial prophylaxis after chemotherapy. J Clin Oncol 2007;25:4821\u20134828."},{"key":"B14","series-title":"Acta Haematol","first-page":"186","article-title":"Fluoroquinolone prophylaxis during conventional chemotherapy or hematopoietic stem cell transplantation for acute leukemia - pros and cons","volume":"147","author":"Hoffman T","year":"2024","unstructured":"Hoffman T, Atamna A, Litchevsky V,  Fluoroquinolone prophylaxis during conventional chemotherapy or hematopoietic stem cell transplantation for acute leukemia - pros and cons. Acta Haematol 2024;147:186\u2013197."},{"key":"B15","series-title":"N Engl J Med","first-page":"2503","article-title":"The new Clostridium difficile\u2013what does it mean?","volume":"353","author":"Bartlett JG","year":"2005","unstructured":"Bartlett JG, Perl TM. The new Clostridium difficile\u2013what does it mean? N Engl J Med 2005;353:2503\u20132505."},{"key":"B16","series-title":"J Hosp Infect","first-page":"348","article-title":"Effect of reduction in ciprofloxacin use on prevalence of meticillin-resistant Staphylococcus aureus rates within individual units of a tertiary care hospital","volume":"64","author":"Cook PP","year":"2006","unstructured":"Cook PP, Catrou P, Gooch M, Holbert D. Effect of reduction in ciprofloxacin use on prevalence of meticillin-resistant Staphylococcus aureus rates within individual units of a tertiary care hospital. J Hosp Infect 2006;64:348\u2013351."},{"key":"B17","series-title":"N Engl J Med","first-page":"2442","article-title":"A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality","volume":"353","author":"Loo VG","year":"2005","unstructured":"Loo VG, Poirier L, Miller MA,  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442\u20132449."},{"key":"B18","series-title":"N Engl J Med","first-page":"2433","article-title":"An epidemic, toxin gene-variant strain of Clostridium difficile","volume":"353","author":"McDonald LC","year":"2005","unstructured":"McDonald LC, Killgore GE, Thompson A,  An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433\u20132441."},{"key":"B19","series-title":"Clin Infect Dis","first-page":"226","article-title":"Guideline for antibacterial prophylaxis administration in pediatric cancer and hematopoietic stem cell transplantation","volume":"71","author":"Lehrnbecher T","year":"2020","unstructured":"Lehrnbecher T, Fisher BT, Phillips B,  Guideline for antibacterial prophylaxis administration in pediatric cancer and hematopoietic stem cell transplantation. Clin Infect Dis 2020;71:226\u2013236."},{"key":"B20","series-title":"Br J Haematol","first-page":"444","article-title":"Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey","volume":"117","author":"Engelhard D","year":"2002","unstructured":"Engelhard D, Cordonnier C, Shaw PJ,  Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol 2002;117:444\u2013450."},{"key":"B21","series-title":"Blood","first-page":"3683","article-title":"Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants","volume":"95","author":"Kulkarni S","year":"2000","unstructured":"Kulkarni S, Powles R, Treleaven J,  Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 2000;95:3683\u20133686."},{"key":"B22","series-title":"Medicine (Baltimore)","first-page":"69","article-title":"Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989\u20132005","volume":"86","author":"Youssef S","year":"2007","unstructured":"Youssef S, Rodriguez G, Rolston KV,  Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989\u20132005. Medicine (Baltimore) 2007;86:69\u201377."},{"key":"B23","series-title":"Bone Marrow Transplant","first-page":"467","article-title":"Bacterial infection prevention after hematopoietic cell transplantation","volume":"44","author":"Engelhard D","year":"2009","unstructured":"Engelhard D, Akova M, Boeckh MJ,  Bacterial infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009;44:467\u2013470."},{"key":"B24","series-title":"J Antimicrob Chemother","first-page":"i7","article-title":"Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001\u20132002, as part of the PROTEKT US study","volume":"54","author":"Brown SD","year":"2004","unstructured":"Brown SD, Rybak MJ. Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001\u20132002, as part of the PROTEKT US study. J Antimicrob Chemother 2004;54(Suppl 1):i7\u201315."},{"key":"B25","series-title":"Medicine (Baltimore)","first-page":"303","article-title":"Streptococcus pneumoniae bacteremia in patients with cancer: disease characteristics and outcomes in the era of escalating drug resistance (1998\u20132002)","volume":"84","author":"Kumashi P","year":"2005","unstructured":"Kumashi P, Girgawy E, Tarrand JJ,  Streptococcus pneumoniae bacteremia in patients with cancer: disease characteristics and outcomes in the era of escalating drug resistance (1998\u20132002). Medicine (Baltimore) 2005;84:303\u2013312."},{"key":"B26","series-title":"Blood","first-page":"5111","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard JR","year":"2010","unstructured":"Wingard JR, Carter SL, Walsh TJ,  Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010;116:5111\u20135118."},{"key":"B27","series-title":"N Engl J Med","first-page":"348","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely OA","year":"2007","unstructured":"Cornely OA, Maertens J, Winston DJ,  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348\u2013359."},{"key":"B28","series-title":"N Engl J Med","first-page":"335","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann AJ","year":"2007","unstructured":"Ullmann AJ, Lipton JH, Vesole DH,  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335\u2013347."},{"key":"B29","series-title":"Clin Infect Dis","first-page":"1179","article-title":"A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV\/AIDS","volume":"42","author":"Vazquez JA","year":"2006","unstructured":"Vazquez JA, Skiest DJ, Nieto L,  A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV\/AIDS. Clin Infect Dis 2006;42:1179\u20131186."},{"key":"B30","series-title":"Lancet","first-page":"499","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens JA","year":"2021","unstructured":"Maertens JA, Rahav G, Lee DG,  Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet 2021;397:499\u2013509."},{"key":"B31","series-title":"JAMA Netw Open","first-page":"e2017652","article-title":"Comparison of antifungal prophylaxis drugs in patients with hematological disease or undergoing hematopoietic stem cell transplantation: a systematic review and network meta-analysis","volume":"3","author":"Wang J","year":"2020","unstructured":"Wang J, Zhou M, Xu JY,  Comparison of antifungal prophylaxis drugs in patients with hematological disease or undergoing hematopoietic stem cell transplantation: a systematic review and network meta-analysis. JAMA Netw Open 2020;3:e2017652."},{"key":"B32","series-title":"Mycoses","first-page":"815","article-title":"A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections","volume":"66","author":"Kato H","year":"2023","unstructured":"Kato H, Hagihara M, Asai N,  A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections. Mycoses 2023;66:815\u2013824."},{"key":"B33","series-title":"J Am Acad Dermatol","first-page":"31","article-title":"Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole","volume":"62","author":"Cowen EW","year":"2010","unstructured":"Cowen EW, Nguyen JC, Miller DD,  Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010;62:31\u201337."},{"key":"B34","series-title":"Blood","first-page":"2390","article-title":"Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole","volume":"120","author":"Gerber B","year":"2012","unstructured":"Gerber B, Guggenberger R, Fasler D,  Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole. Blood 2012;120:2390\u20132394."},{"key":"B35","series-title":"Arch Dermatol","first-page":"300","article-title":"Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity","volume":"146","author":"Miller DD","year":"2010","unstructured":"Miller DD, Cowen EW, Nguyen JC,  Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol 2010;146:300\u2013304."},{"key":"B36","series-title":"Pediatr Blood Cancer","first-page":"918","article-title":"Elevated fluoride levels and periostitis in pediatric hematopoietic stem cell transplant recipients receiving long-term voriconazole","volume":"62","author":"Tarlock K","year":"2015","unstructured":"Tarlock K, Johnson D, Cornell C,  Elevated fluoride levels and periostitis in pediatric hematopoietic stem cell transplant recipients receiving long-term voriconazole. Pediatr Blood Cancer 2015;62:918\u2013920."},{"key":"B37","series-title":"Clin Infect Dis","first-page":"997","article-title":"Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients","volume":"58","author":"Williams K","year":"2014","unstructured":"Williams K, Mansh M, Chin-Hong P,  Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis 2014;58:997\u20131002."},{"key":"B38","series-title":"Blood","first-page":"1527","article-title":"Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants","volume":"103","author":"Marr KA","year":"2004","unstructured":"Marr KA, Crippa F, Leisenring W,  Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103:1527\u20131533."},{"key":"B39","series-title":"Blood","first-page":"1557","article-title":"Cyclophosphamide metabolism is affected by azole antifungals","volume":"103","author":"Marr KA","year":"2004","unstructured":"Marr KA, Leisenring W, Crippa F,  Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004;103:1557\u20131559."},{"key":"B40","series-title":"Heart","first-page":"1363","article-title":"Drug induced QT prolongation and torsades de pointes","volume":"89","author":"Yap YG","year":"2003","unstructured":"Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89:1363\u20131372."},{"key":"B41","series-title":"Ther Drug Monit","first-page":"166","article-title":"Antifungal drugs TDM: trends and update","volume":"44","author":"Kably B","year":"2022","unstructured":"Kably B, Launay M, Derobertmasure A,  Antifungal drugs TDM: trends and update. Ther Drug Monit 2022;44:166\u2013197."},{"key":"B42","series-title":"Antimicrob Agents Chemother","first-page":"2116","article-title":"Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model","volume":"43","author":"Andes D","year":"1999","unstructured":"Andes D, van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 1999;43:2116\u20132120."},{"key":"B43","series-title":"Antimicrob Agents Chemother","first-page":"3171","article-title":"Fluconazole MIC and the fluconazole dose\/MIC ratio correlate with therapeutic response among patients with candidemia","volume":"49","author":"Clancy CJ","year":"2005","unstructured":"Clancy CJ, Yu VL, Morris AJ,  Fluconazole MIC and the fluconazole dose\/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 2005;49:3171\u20133177."},{"key":"B44","series-title":"Eur J Clin Pharmacol","first-page":"723","article-title":"Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients","volume":"57","author":"Csajka C","year":"2001","unstructured":"Csajka C, Decosterd LA, Buclin T,  Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients. Eur J Clin Pharmacol 2001;57:723\u2013727."},{"key":"B45","series-title":"Clin Infect Dis","first-page":"235","article-title":"Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards","volume":"24","author":"Rex JH","year":"1997","unstructured":"Rex JH, Pfaller MA, Galgiani JN,  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997;24:235\u2013247."},{"key":"B46","series-title":"Antimicrob Agents Chemother","first-page":"958","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna G","year":"2009","unstructured":"Krishna G, Moton A, Ma L,  Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009;53:958\u2013966."},{"key":"B47","series-title":"Pharmacotherapy","first-page":"1117","article-title":"Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature","volume":"33","author":"Gross BN","year":"2013","unstructured":"Gross BN, Ihorst G, Jung M,  Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature. Pharmacotherapy 2013;33:1117\u20131125."},{"key":"B48","series-title":"Int J Antimicrob Agents","first-page":"266","article-title":"A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis","volume":"37","author":"Bryant AM","year":"2011","unstructured":"Bryant AM, Slain D, Cumpston A, Craig M. A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis. Int J Antimicrob Agents 2011;37:266\u2013269."},{"key":"B49","series-title":"Antimicrob Agents Chemother","first-page":"303","article-title":"International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations","volume":"53","author":"Bruggemann RJ","year":"2009","unstructured":"Bruggemann RJ, Touw DJ, Aarnoutse RE,  International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother 2009;53:303\u2013305."},{"key":"B50","series-title":"Antimicrob Agents Chemother","first-page":"4020","article-title":"Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects","volume":"58","author":"Kraft WK","year":"2014","unstructured":"Kraft WK, Chang PS, van Iersel ML,  Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. Antimicrob Agents Chemother 2014;58:4020\u20134025."},{"key":"B51","series-title":"Mycoses","first-page":"304","article-title":"Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis","volume":"56","author":"Heinz WJ","year":"2013","unstructured":"Heinz WJ, Egerer G, Lellek H,  Posaconazole after previous antifungal therapy with voriconazole for therapy of invasive aspergillus disease, a retrospective analysis. Mycoses 2013;56:304\u2013310."},{"key":"B52","series-title":"Antimicrob Agents Chemother","first-page":"3610","article-title":"Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease","volume":"58","author":"Maertens J","year":"2014","unstructured":"Maertens J, Cornely OA, Ullmann AJ,  Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrob Agents Chemother 2014;58:3610\u20133617."},{"key":"B53","series-title":"Clin Pharmacol Ther","first-page":"115","article-title":"Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma","volume":"88","author":"Jang SH","year":"2010","unstructured":"Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010;88:115\u2013119."},{"key":"B54","series-title":"Antimicrob Agents Chemother","first-page":"5247","article-title":"Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease","volume":"56","author":"Tonini J","year":"2012","unstructured":"Tonini J, Thiebaut A, Jourdil JF,  Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease. Antimicrob Agents Chemother 2012;56:5247\u20135252."},{"key":"B55","series-title":"Antimicrob Agents Chemother","first-page":"1308","article-title":"Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy","volume":"55","author":"Shields RK","year":"2011","unstructured":"Shields RK, Clancy CJ, Vadnerkar A,  Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. Antimicrob Agents Chemother 2011;55:1308\u20131311."},{"key":"B56","series-title":"Eur J Clin Microbiol Infect Dis","first-page":"161","article-title":"Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake","volume":"31","author":"Eiden C","year":"2012","unstructured":"Eiden C, Meniane JC, Peyriere H,  Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake. Eur J Clin Microbiol Infect Dis 2012;31:161\u2013167."},{"key":"B57","series-title":"Int J Antimicrob Agents","first-page":"510","article-title":"Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies","volume":"39","author":"Hoenigl M","year":"2012","unstructured":"Hoenigl M, Raggam RB, Salzer HJ,  Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. Int J Antimicrob Agents 2012;39:510\u2013513."},{"key":"B58","series-title":"Antimicrob Agents Chemother","first-page":"5224","article-title":"Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults","volume":"53","author":"Lebeaux D","year":"2009","unstructured":"Lebeaux D, Lanternier F, Elie C,  Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother 2009;53:5224\u20135229."},{"key":"B59","series-title":"Emerg Infect Dis","first-page":"1068","article-title":"Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard SJ","year":"2009","unstructured":"Howard SJ, Cerar D, Anderson MJ,  Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009;15:1068\u20131076."},{"key":"B60","series-title":"Antimicrob Agents Chemother","first-page":"860","article-title":"Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene","volume":"54","author":"Mavridou E","year":"2010","unstructured":"Mavridou E, Bruggemann RJ, Melchers WJ,  Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother 2010;54:860\u2013865."},{"key":"B61","series-title":"Mycoses","first-page":"103","article-title":"Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels","volume":"32","author":"Boogaerts MA","year":"1989","unstructured":"Boogaerts MA, Verhoef GE, Zachee P,  Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989;32(Suppl 1):103\u2013108."},{"key":"B62","series-title":"Rev Infect Dis","first-page":"S94","article-title":"Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies","volume":"9","author":"Tricot G","year":"1987","unstructured":"Tricot G, Joosten E, Boogaerts MA,  Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis 1987;9(Suppl 1):S94\u201399."},{"key":"B63","series-title":"Mycoses","first-page":"443","article-title":"Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole","volume":"42","author":"Glasmacher A","year":"1999","unstructured":"Glasmacher A, Hahn C, Leutner C,  Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999;42:443\u2013451."},{"key":"B64","series-title":"Mycoses","first-page":"591","article-title":"Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules","volume":"42","author":"Glasmacher A","year":"1999","unstructured":"Glasmacher A, Hahn C, Molitor E,  Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses 1999;42:591\u2013600."},{"key":"B65","series-title":"Arch Intern Med","first-page":"2301","article-title":"Itraconazole therapy for cryptococcal meningitis and cryptococcosis","volume":"149","author":"Denning DW","year":"1989","unstructured":"Denning DW, Tucker RM, Hanson LH,  Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med 1989;149:2301\u20132308."},{"key":"B66","series-title":"Am J Med","first-page":"791","article-title":"Treatment of invasive aspergillosis with itraconazole","volume":"86","author":"Denning DW","year":"1989","unstructured":"Denning DW, Tucker RM, Hanson LH, Stevens DA. Treatment of invasive aspergillosis with itraconazole. Am J Med 1989;86:791\u2013800."},{"key":"B67","series-title":"Antimicrob Agents Chemother","first-page":"707","article-title":"High-dose itraconazole in the treatment of severe mycoses","volume":"35","author":"Sharkey PK","year":"1991","unstructured":"Sharkey PK, Rinaldi MG, Dunn JF,  High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 1991;35:707\u2013713."},{"key":"B68","series-title":"Am J Med","first-page":"336","article-title":"Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group","volume":"98","author":"Wheat J","year":"1995","unstructured":"Wheat J, Hafner R, Korzun AH,  Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med 1995;98: 336\u2013342."},{"key":"B69","series-title":"Clin Infect Dis","first-page":"928","article-title":"Toxicodynamics of itraconazole: implications for therapeutic drug monitoring","volume":"49","author":"Lestner JM","year":"2009","unstructured":"Lestner JM, Roberts SA, Moore CB,  Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis 2009;49:928\u2013930."},{"key":"B70","series-title":"Pharmacotherapy","first-page":"295","article-title":"Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers","volume":"18","author":"Barone JA","year":"1998","unstructured":"Barone JA, Moskovitz BL, Guarnieri J,  Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy 1998;18:295\u2013301."},{"key":"B71","series-title":"Open Forum Infect Dis","first-page":"ofab502","article-title":"SUBA-itraconazole for primary antifungal prophylaxis after allogeneic hematopoietic cell transplantation","volume":"8","author":"Lindsay J","year":"2021","unstructured":"Lindsay J, Othman J, Kong Y,  SUBA-itraconazole for primary antifungal prophylaxis after allogeneic hematopoietic cell transplantation. Open Forum Infect Dis 2021;8:ofab502."},{"key":"B72","series-title":"Future Microbiol","first-page":"1171","article-title":"SUBA-itraconazole in the treatment of systemic fungal infections","volume":"19","author":"Liu J","year":"2024","unstructured":"Liu J, Vanderwyk KA, Donnelley MA, Thompson GR III. SUBA-itraconazole in the treatment of systemic fungal infections. Future Microbiol 2024;19:1171\u20131175."},{"key":"B73","series-title":"Clin Infect Dis","first-page":"201","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual A","year":"2008","unstructured":"Pascual A, Calandra T, Bolay S,  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201\u2013211."},{"key":"B74","series-title":"Antimicrob Agents Chemother","first-page":"5180","article-title":"Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis","volume":"56","author":"Jeans AR","year":"2012","unstructured":"Jeans AR, Howard SJ, Al-Nakeeb Z,  Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2012;56:5180\u20135185."},{"key":"B75","series-title":"Antimicrob Agents Chemother","first-page":"1570","article-title":"Voriconazole therapeutic drug monitoring","volume":"50","author":"Smith J","year":"2006","unstructured":"Smith J, Safdar N, Knasinski V,  Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006;50:1570\u20131572."},{"key":"B76","series-title":"Antimicrob Agents Chemother","first-page":"4782","article-title":"Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients","volume":"55","author":"Troke PF","year":"2011","unstructured":"Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 2011;55:4782\u20134788."},{"key":"B77","series-title":"Antimicrob Agents Chemother","first-page":"4793","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton MJ","year":"2012","unstructured":"Dolton MJ, Ray JE, Chen SC,  Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring. Antimicrob Agents Chemother 2012;56:4793\u20134799."},{"key":"B78","series-title":"Clin Microbiol Infect","first-page":"927","article-title":"Voriconazole concentrations and outcome of invasive fungal infections","volume":"16","author":"Miyakis S","year":"2010","unstructured":"Miyakis S, van Hal SJ, Ray J, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect 2010;16:927\u2013933."},{"key":"B79","series-title":"Med Mycol","first-page":"439","article-title":"Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients","volume":"50","author":"Gomez-Lopez A","year":"2012","unstructured":"Gomez-Lopez A, Cendejas-Bueno E, Cuesta I,  Voriconazole serum levels measured by high-performance liquid chromatography: a monocentric study in treated patients. Med Mycol 2012;50:439\u2013445."},{"key":"B80","series-title":"Int J Hematol","first-page":"592","article-title":"Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders","volume":"89","author":"Ueda K","year":"2009","unstructured":"Ueda K, Nannya Y, Kumano K,  Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 2009;89:592\u2013599."},{"key":"B81","series-title":"Bone Marrow Transplant","first-page":"451","article-title":"Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole","volume":"40","author":"Trifilio S","year":"2007","unstructured":"Trifilio S, Singhal S, Williams S,  Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007;40:451\u2013456."},{"key":"B82","series-title":"Antimicrob Agents Chemother","first-page":"2371","article-title":"Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity","volume":"56","author":"Mitsani D","year":"2012","unstructured":"Mitsani D, Nguyen MH, Shields RK,  Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother 2012;56:2371\u20132377."},{"key":"B83","series-title":"Clin Infect Dis","first-page":"381","article-title":"Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections","volume":"55","author":"Pascual A","year":"2012","unstructured":"Pascual A, Csajka C, Buclin T,  Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 2012;55:381\u2013390."},{"key":"B84","series-title":"Clin Infect Dis","first-page":"e7","article-title":"Hallucinations during voriconazole therapy","volume":"47","author":"Zonios DI","year":"2008","unstructured":"Zonios DI, Gea-Banacloche J, Childs R, Bennett JE. Hallucinations during voriconazole therapy. Clin Infect Dis 2008;47:e7\u201310."},{"key":"B85","series-title":"J Infect Chemother","first-page":"501","article-title":"Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis","volume":"18","author":"Hamada Y","year":"2012","unstructured":"Hamada Y, Seto Y, Yago K, Kuroyama M. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis. J Infect Chemother 2012;18:501\u2013507."},{"key":"B86","series-title":"Med Mycol","first-page":"103","article-title":"Voriconazole-associated severe hyponatremia","volume":"50","author":"Kim KH","year":"2012","unstructured":"Kim KH, Lee S, Lee S,  Voriconazole-associated severe hyponatremia. Med Mycol 2012;50:103\u2013105."},{"key":"B87","series-title":"Int J Antimicrob Agents","first-page":"91","article-title":"Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes","volume":"34","author":"Matsumoto K","year":"2009","unstructured":"Matsumoto K, Ikawa K, Abematsu K,  Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. Int J Antimicrob Agents 2009;34:91\u201394."},{"key":"B88","series-title":"Br J Clin Pharmacol","first-page":"17","article-title":"Effect of food on the pharmacokinetics of multiple-dose oral voriconazole","volume":"56","author":"Purkins L","year":"2003","unstructured":"Purkins L, Wood N, Kleinermans D,  Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003;56(Suppl 1):17\u201323."},{"key":"B89","series-title":"Pharmacotherapy","first-page":"1043","article-title":"Utility of triazole antifungal therapeutic drug monitoring: insights from the Society of Infectious Diseases Pharmacists: endorsed by the Mycoses Study Group Education and Research Consortium","volume":"43","author":"McCreary EK","year":"2023","unstructured":"McCreary EK, Davis MR, Narayanan N,  Utility of triazole antifungal therapeutic drug monitoring: insights from the Society of Infectious Diseases Pharmacists: endorsed by the Mycoses Study Group Education and Research Consortium. Pharmacotherapy 2023;43:1043\u20131050."},{"key":"B90","series-title":"Am J Hematol","first-page":"260","article-title":"Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation","volume":"71","author":"Koh LP","year":"2002","unstructured":"Koh LP, Kurup A, Goh YT,  Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol 2002;71:260\u2013267."},{"key":"B91","series-title":"Ann Intern Med","first-page":"705","article-title":"Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial","volume":"138","author":"Winston DJ","year":"2003","unstructured":"Winston DJ, Maziarz RT, Chandrasekar PH,  Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003;138:705\u2013713."},{"key":"B92","series-title":"Kidney Int","first-page":"1452","article-title":"Correlates of acute renal failure in patients receiving parenteral amphotericin B","volume":"60","author":"Bates DW","year":"2001","unstructured":"Bates DW, Su L, Yu DT,  Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int 2001;60:1452\u20131459."},{"key":"B93","series-title":"Clin Infect Dis","first-page":"1402","article-title":"Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis","volume":"29","author":"Wingard JR","year":"1999","unstructured":"Wingard JR, Kubilis P, Lee L,  Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402\u20131407."},{"key":"B94","series-title":"Clin Infect Dis","first-page":"1401","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial","volume":"46","author":"Rijnders BJ","year":"2008","unstructured":"Rijnders BJ, Cornelissen JJ, Slobbe L,  Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008;46:1401\u20131408."},{"key":"B95","series-title":"Clin Infect Dis","first-page":"1409","article-title":"Aerosolized antifungal prophylaxis: the winds of change?","volume":"46","author":"Perfect JR","year":"2008","unstructured":"Perfect JR. Aerosolized antifungal prophylaxis: the winds of change? Clin Infect Dis 2008;46:1409\u20131411."},{"key":"B96","series-title":"Rev Iberoam Micol","first-page":"121","article-title":"In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature","volume":"20","author":"Espinel-Ingroff A","year":"2003","unstructured":"Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003;20:121\u2013136."},{"key":"B97","series-title":"Clin Infect Dis","first-page":"1529","article-title":"A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis","volume":"33","author":"Villanueva A","year":"2001","unstructured":"Villanueva A, Arathoon EG, Gotuzzo E,  A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001;33:1529\u20131535."},{"key":"B98","series-title":"Clin Infect Dis","first-page":"1563","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy","volume":"39","author":"Maertens J","year":"2004","unstructured":"Maertens J, Raad I, Petrikkos G,  Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39:1563\u20131571."},{"key":"B99","series-title":"J Infect","first-page":"196","article-title":"Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study","volume":"50","author":"Kartsonis NA","year":"2005","unstructured":"Kartsonis NA, Saah AJ, Joy Lipka C,  Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 2005;50:196\u2013205."},{"key":"B100","series-title":"Clin Infect Dis","first-page":"1407","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik JH","year":"2004","unstructured":"van Burik JH, Ratanatharathorn V, Stepan DE,  Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407\u20131416."},{"key":"B101","series-title":"Ann Hematol","first-page":"64","article-title":"Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy","volume":"83","author":"Yokote T","year":"2004","unstructured":"Yokote T, Akioka T, Oka S,  Successful treatment with micafungin of invasive pulmonary aspergillosis in acute myeloid leukemia, with renal failure due to amphotericin B therapy. Ann Hematol 2004;83:64\u201366."},{"key":"B102","series-title":"Int J Hematol","first-page":"390","article-title":"Successful micafungin (FK463) treatment of invasive pulmonary aspergillosis in a patient with acute lymphoblastic leukemia in a phase II study","volume":"79","author":"Ota S","year":"2004","unstructured":"Ota S, Tanaka J, Kahata K,  Successful micafungin (FK463) treatment of invasive pulmonary aspergillosis in a patient with acute lymphoblastic leukemia in a phase II study. Int J Hematol 2004;79:390\u2013393."},{"key":"B103","series-title":"J Pediatr Hematol Oncol","first-page":"252","article-title":"Successful treatment of invasive aspergillosis in two patients with acute myelogenous leukemia","volume":"25","author":"Singer MS","year":"2003","unstructured":"Singer MS, Seibel NL, Vezina G,  Successful treatment of invasive aspergillosis in two patients with acute myelogenous leukemia. J Pediatr Hematol Oncol 2003;25:252\u2013256."},{"key":"B104","series-title":"Clin Infect Dis","first-page":"770","article-title":"A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis","volume":"39","author":"Krause DS","year":"2004","unstructured":"Krause DS, Simjee AE, van Rensburg C,  A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004;39:770\u2013775."},{"key":"B105","series-title":"J Acquir Immune Defic Syndr","first-page":"304","article-title":"A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis","volume":"48","author":"Vazquez JA","year":"2008","unstructured":"Vazquez JA, Schranz JA, Clark K,  A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J Acquir Immune Defic Syndr 2008;48:304\u2013309."},{"key":"B106","series-title":"N Engl J Med","first-page":"2472","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli AC","year":"2007","unstructured":"Reboli AC, Rotstein C, Pappas PG,  Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356:2472\u20132482."},{"key":"B107","series-title":"Lancet","first-page":"49","article-title":"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson GR","year":"2023","unstructured":"Thompson GR, Soriano A, Cornely OA,  Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet 2023;401:49\u201359."},{"key":"B108","series-title":"J Oncol Pharm Pract","first-page":"175","article-title":"Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients","volume":"15","author":"Harnicar S","year":"2009","unstructured":"Harnicar S, Adel N, Jurcic J. Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients. J Oncol Pharm Pract 2009;15:175\u2013182."},{"key":"B109","series-title":"Am J Med","first-page":"380","article-title":"The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer","volume":"112","author":"Bodey GP","year":"2002","unstructured":"Bodey GP, Mardani M, Hanna HA,  The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002;112:380\u2013385."},{"key":"B110","series-title":"J Infect Dis","first-page":"309","article-title":"Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole","volume":"181","author":"Marr KA","year":"2000","unstructured":"Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000;181:309\u2013316."},{"key":"B111","series-title":"Blood","first-page":"2055","article-title":"Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial","volume":"96","author":"Marr KA","year":"2000","unstructured":"Marr KA, Seidel K, Slavin MA,  Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2055\u20132061."},{"key":"B112","series-title":"Ann Hematol","first-page":"1435","article-title":"Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016","volume":"95","author":"Ullmann AJ","year":"2016","unstructured":"Ullmann AJ, Schmidt-Hieber M, Bertz H,  Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol 2016;95:1435\u20131455."},{"key":"B113","series-title":"J Antimicrob Chemother","first-page":"1813","article-title":"Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"78","author":"Stemler J","year":"2023","unstructured":"Stemler J, Mellinghoff SC, Khodamoradi Y,  Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). J Antimicrob Chemother 2023;78:1813\u20131826."},{"key":"B114","series-title":"Medicine (Baltimore)","first-page":"24","article-title":"Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death","volume":"71","author":"Weinberger M","year":"1992","unstructured":"Weinberger M, Elattar I, Marshall D,  Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore) 1992;71:24\u201343."},{"key":"B115","series-title":"Cancer","first-page":"2357","article-title":"Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia","volume":"76","author":"Walsh TJ","year":"1995","unstructured":"Walsh TJ, Whitcomb PO, Revankar SG, Pizzo PA. Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia. Cancer 1995;76:2357\u20132362."},{"key":"B116","series-title":"Clin Infect Dis","first-page":"1098","article-title":"Impact of previous aspergillosis on the outcome of bone marrow transplantation","volume":"26","author":"Offner F","year":"1998","unstructured":"Offner F, Cordonnier C, Ljungman P,  Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998;26:1098\u20131103."},{"key":"B117","series-title":"Biol Blood Marrow Transplant","first-page":"494","article-title":"Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center","volume":"10","author":"Fukuda T","year":"2004","unstructured":"Fukuda T, Boeckh M, Guthrie KA,  Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. Biol Blood Marrow Transplant 2004;10:494\u2013503."},{"key":"B118","series-title":"J Infect Dis","first-page":"338","article-title":"Infection with herpes simplex virus and cell-mediated immunity after marrow transplant","volume":"142","author":"Meyers JD","year":"1980","unstructured":"Meyers JD, Flournoy N, Thomas ED. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis 1980;142:338\u2013346."},{"key":"B119","series-title":"N Engl J Med","first-page":"63","article-title":"Acyclovir prophylaxis of herpes-simplex-virus infections","volume":"305","author":"Saral R","year":"1981","unstructured":"Saral R, Burns WH, Laskin OL,  Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981;305:63\u201367."},{"key":"B120","series-title":"Ann Intern Med","first-page":"773","article-title":"Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study","volume":"99","author":"Saral R","year":"1983","unstructured":"Saral R, Ambinder RF, Burns WH,  Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med 1983;99:773\u2013776."},{"key":"B121","series-title":"Bone Marrow Transplant","first-page":"457","article-title":"Background to hematopoietic cell transplantation, including post transplant immune recovery","volume":"44","author":"Mackall C","year":"2009","unstructured":"Mackall C, Fry T, Gress R,  Background to hematopoietic cell transplantation, including post transplant immune recovery. Bone Marrow Transplant 2009;44:457\u2013462."},{"key":"B122","series-title":"Biol Blood Marrow Transplant","first-page":"1143","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn M","year":"2009","unstructured":"Tomblyn M, Chiller T, Einsele H,  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:1143\u20131238."},{"key":"B123","series-title":"Hematology Am Soc Hematol Educ Program","first-page":"392","article-title":"Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond","author":"Sullivan KM","year":"2001","unstructured":"Sullivan KM, Dykewicz CA, Longworth DL,  Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology Am Soc Hematol Educ Program 2001:392\u2013421."},{"key":"B124","series-title":"Bone Marrow Transplant","first-page":"471","article-title":"Viral disease prevention after hematopoietic cell transplantation","volume":"44","author":"Zaia J","year":"2009","unstructured":"Zaia J, Baden L, Boeckh MJ,  Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009;44:471\u2013482."},{"key":"B125","series-title":"Clin Lymphoma","first-page":"220","article-title":"Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia","volume":"4","author":"Keating M","year":"2004","unstructured":"Keating M, Coutre S, Rai K,  Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004;4:220\u2013227."},{"key":"B126","series-title":"Blood","first-page":"1800","article-title":"Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation\u2013a randomized double-blind placebo-controlled study","volume":"107","author":"Boeckh M","year":"2006","unstructured":"Boeckh M, Kim HW, Flowers MED,  Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation\u2013a randomized double-blind placebo-controlled study. Blood 2006;107:1800\u20131805."},{"key":"B127","series-title":"Blood","first-page":"3071","article-title":"One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation","volume":"110","author":"Erard V","year":"2007","unstructured":"Erard V, Guthrie KA, Varley C,  One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007;110:3071\u20133077."},{"key":"B128","series-title":"Am J Hematol","first-page":"472","article-title":"Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation","volume":"83","author":"Asano-Mori Y","year":"2008","unstructured":"Asano-Mori Y, Kanda Y, Oshima K,  Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2008;83:472\u2013476."},{"key":"B129","series-title":"Transpl Infect Dis","first-page":"421","article-title":"One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group","volume":"12","author":"Oshima K","year":"2010","unstructured":"Oshima K, Takahashi T, Mori T,  One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group. Transpl Infect Dis 2010;12:421\u2013427."},{"key":"B130","series-title":"Blood","first-page":"1424","article-title":"Herpes zoster infection after autologous bone marrow transplantation","volume":"74","author":"Schuchter LM","year":"1989","unstructured":"Schuchter LM, Wingard JR, Piantadosi S,  Herpes zoster infection after autologous bone marrow transplantation. Blood 1989;74:1424\u20131427."},{"key":"B131","series-title":"J Clin Oncol","first-page":"4784","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan A","year":"2008","unstructured":"Chanan-Khan A, Sonneveld P, Schuster MW,  Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008;26:4784\u20134790."},{"key":"B132","series-title":"J Clin Oncol","first-page":"4777","article-title":"Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma","volume":"26","author":"Reece DE","year":"2008","unstructured":"Reece DE, Rodriguez GP, Chen C,  Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008;26:4777\u20134783."},{"key":"B133","series-title":"Am J Hematol","first-page":"403","article-title":"The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients","volume":"82","author":"Tong Y","year":"2007","unstructured":"Tong Y, Qian J, Li Y,  The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. Am J Hematol 2007;82:403\u2013404."},{"key":"B134","series-title":"Ann Hematol","first-page":"301","article-title":"Late onset of bortezomib-associated cutaneous reaction following herpes zoster","volume":"86","author":"Varettoni M","year":"2007","unstructured":"Varettoni M, Vassallo C, Borroni G,  Late onset of bortezomib-associated cutaneous reaction following herpes zoster. Ann Hematol 2007;86:301\u2013302."},{"key":"B135","series-title":"Clin Lymphoma Myeloma","first-page":"151","article-title":"Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib","volume":"9","author":"Pour L","year":"2009","unstructured":"Pour L, Adam Z, Buresova L,  Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma 2009;9:151\u2013153."},{"key":"B136","series-title":"Cancer","first-page":"229","article-title":"Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy","volume":"115","author":"Vickrey E","year":"2009","unstructured":"Vickrey E, Allen S, Mehta J, Singhal S. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 2009;115:229\u2013232."},{"key":"B137","series-title":"Transpl Infect Dis","first-page":"322","article-title":"Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy","volume":"12","author":"George B","year":"2010","unstructured":"George B, Pati N, Gilroy N,  Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis 2010;12:322\u2013329."},{"key":"B138","series-title":"Biol Blood Marrow Transplant","first-page":"215","article-title":"Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation","volume":"16","author":"Beck JC","year":"2010","unstructured":"Beck JC, Wagner JE, DeFor TE,  Impact of cytomegalovirus (CMV) reactivation after umbilical cord blood transplantation. Biol Blood Marrow Transplant 2010;16:215\u2013222."},{"key":"B139","series-title":"Blood","first-page":"5689","article-title":"Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients","volume":"118","author":"Milano F","year":"2011","unstructured":"Milano F, Pergam SA, Xie H,  Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood 2011;118:5689\u20135696."},{"key":"B140","series-title":"Biol Blood Marrow Transplant","first-page":"730","article-title":"Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation","volume":"15","author":"Montesinos P","year":"2009","unstructured":"Montesinos P, Sanz J, Cantero S,  Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation. Biol Blood Marrow Transplant 2009;15:730\u2013740."},{"key":"B141","series-title":"N Engl J Med","first-page":"1781","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly RF","year":"2014","unstructured":"Chemaly RF, Ullmann AJ, Stoelben S,  Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 2014;370:1781\u20131789."},{"key":"B142","series-title":"N Engl J Med","first-page":"2433","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty FM","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF,  Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med 2017;377:2433\u20132444."},{"key":"B143","series-title":"J Antimicrob Chemother","first-page":"2253","article-title":"Letermovir breakthroughs during the French Named Patient Programme: interest of monitoring blood concentration in clinical practice","volume":"75","author":"Alain S","year":"2020","unstructured":"Alain S, Feghoul L, Girault S,  Letermovir breakthroughs during the French Named Patient Programme: interest of monitoring blood concentration in clinical practice. J Antimicrob Chemother 2020;75:2253\u20132257."},{"key":"B144","series-title":"Am J Transplant","first-page":"3060","article-title":"Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection","volume":"18","author":"Cherrier L","year":"2018","unstructured":"Cherrier L, Nasar A, Goodlet KJ,  Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. Am J Transplant 2018;18:3060\u20133064."},{"key":"B145","series-title":"Mediterr J Hematol Infect Dis","first-page":"e2019001","article-title":"In vivo emergence of UL56 C325Y cytomegalovirus resistance to letermovir in a patient with acute myeloid leukemia after hematopoietic cell transplantation","volume":"11","author":"Frietsch JJ","year":"2019","unstructured":"Frietsch JJ, Michel D, Stamminger T,  In vivo emergence of UL56 C325Y cytomegalovirus resistance to letermovir in a patient with acute myeloid leukemia after hematopoietic cell transplantation. Mediterr J Hematol Infect Dis 2019;11:e2019001."},{"key":"B146","series-title":"Blood","first-page":"1159","article-title":"Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation","volume":"99","author":"Reusser P","year":"2002","unstructured":"Reusser P, Einsele H, Lee J,  Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002;99:1159\u20131164."},{"key":"B147","series-title":"J Infect Dis","first-page":"473","article-title":"Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients","volume":"166","author":"Reusser P","year":"1992","unstructured":"Reusser P, Gambertoglio JG, Lilleby K, Meyers JD. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis 1992;166:473\u2013479."},{"key":"B148","series-title":"Bone Marrow Transplant","first-page":"783","article-title":"CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections","volume":"13","author":"Bacigalupo A","year":"1994","unstructured":"Bacigalupo A, Tedone E, Van Lint MT,  CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant 1994;13:783\u2013788."},{"key":"B149","series-title":"Bone Marrow Transplant","first-page":"23","article-title":"Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study","volume":"26","author":"Bregante S","year":"2000","unstructured":"Bregante S, Bertilson S, Tedone E,  Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study. Bone Marrow Transplant 2000;26:23\u201329."},{"key":"B150","series-title":"Blood","first-page":"3002","article-title":"Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation","volume":"107","author":"Einsele H","year":"2006","unstructured":"Einsele H, Reusser P, Bornhauser M,  Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 2006;107:3002\u20133008."},{"key":"B151","series-title":"Biol Blood Marrow Transplant","first-page":"635","article-title":"Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract","volume":"12","author":"Winston DJ","year":"2006","unstructured":"Winston DJ, Baden LR, Gabriel DA,  Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract. Biol Blood Marrow Transplant 2006;12:635\u2013640."},{"key":"B152","series-title":"Bone Marrow Transplant","first-page":"851","article-title":"Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation","volume":"37","author":"Ayala E","year":"2006","unstructured":"Ayala E, Greene J, Sandin R,  Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006;37:851\u2013856."},{"key":"B153","series-title":"Transpl Infect Dis","first-page":"102","article-title":"Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation","volume":"9","author":"Busca A","year":"2007","unstructured":"Busca A, de Fabritiis P, Ghisetti V,  Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. Transpl Infect Dis 2007;9:102\u2013107."},{"key":"B154","series-title":"Bone Marrow Transplant","first-page":"693","article-title":"Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients","volume":"37","author":"van der Heiden PLJ","year":"2006","unstructured":"van der Heiden PLJ, Kalpoe JS, Barge RM,  Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant 2006;37:693\u2013698."},{"key":"B155","series-title":"PLoS One","first-page":"e5512","article-title":"Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy","volume":"4","author":"Kalil AC","year":"2009","unstructured":"Kalil AC, Freifeld AG, Lyden ER, Stoner JA. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS One 2009;4:e5512."},{"key":"B156","series-title":"Liver Transpl","first-page":"1440","article-title":"Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis","volume":"18","author":"Kalil AC","year":"2012","unstructured":"Kalil AC, Mindru C, Botha JF,  Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis. Liver Transpl 2012;18:1440\u20131447."},{"key":"B157","series-title":"Haematologica","first-page":"446","article-title":"Polymerase chain reaction-based \u201cpre-emptive\u201d therapy with cidofovir for cytomegalovirus reactivation in allogeneic hematopoietic stem cells transplantation recipients: a prospective study","volume":"87","author":"Bosi A","year":"2002","unstructured":"Bosi A, Bartolozzi B, Vannucchi AM,  Polymerase chain reaction-based \u201cpre-emptive\u201d therapy with cidofovir for cytomegalovirus reactivation in allogeneic hematopoietic stem cells transplantation recipients: a prospective study. Haematologica 2002;87:446\u2013447."},{"key":"B158","series-title":"Bone Marrow Transplant","first-page":"879","article-title":"Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections","volume":"28","author":"Chakrabarti S","year":"2001","unstructured":"Chakrabarti S, Collingham KE, Osman H,  Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections. Bone Marrow Transplant 2001;28:879\u2013881."},{"key":"B159","series-title":"Blood","first-page":"388","article-title":"Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation","volume":"97","author":"Ljungman P","year":"2001","unstructured":"Ljungman P, Deliliers GL, Platzbecker U,  Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2001;97:388\u2013392."},{"key":"B160","series-title":"Transplantation","first-page":"880","article-title":"Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation","volume":"71","author":"Platzbecker U","year":"2001","unstructured":"Platzbecker U, Bandt D, Thiede C,  Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation. Transplantation 2001;71:880\u2013885."},{"key":"B161","series-title":"Clin Infect Dis","first-page":"1255","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study","volume":"68","author":"Papanicolaou GA","year":"2019","unstructured":"Papanicolaou GA, Silveira FP, Langston AA,  Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study. Clin Infect Dis 2019;68:1255\u20131264."},{"key":"B162","series-title":"Clin Infect Dis","first-page":"690","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery RK","year":"2022","unstructured":"Avery RK, Alain S, Alexander BD,  Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin Infect Dis 2022;75:690\u2013701."},{"key":"B163","series-title":"Clin Infect Dis","first-page":"562","article-title":"Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir","volume":"78","author":"Papanicolaou GA","year":"2024","unstructured":"Papanicolaou GA, Avery RK, Cordonnier C,  Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir. Clin Infect Dis 2024;78:562\u2013572."},{"key":"B164","series-title":"Haematologica","first-page":"1248","article-title":"Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir","volume":"89","author":"Laurenti L","year":"2004","unstructured":"Laurenti L, Piccioni P, Cattani P,  Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica 2004;89:1248\u20131252."},{"key":"B165","series-title":"J Clin Oncol","first-page":"2971","article-title":"Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival","volume":"23","author":"Moreton P","year":"2005","unstructured":"Moreton P, Kennedy B, Lucas G,  Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005;23:2971\u20132979."},{"key":"B166","series-title":"Clin Lymphoma","first-page":"105","article-title":"Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia","volume":"3","author":"Nguyen DD","year":"2002","unstructured":"Nguyen DD, Cao TM, Dugan K,  Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma 2002;3:105\u2013110."},{"key":"B167","series-title":"Blood","first-page":"1816","article-title":"Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy","volume":"111","author":"O\u2019Brien S","year":"2008","unstructured":"O\u2019Brien S, Ravandi F, Riehl T,  Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 2008;111:1816\u20131819."},{"key":"B168","series-title":"Lancet Infect Dis","first-page":"e260","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman P","year":"2019","unstructured":"Ljungman P, de la Camara R, Robin C,  Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 2019;19:e260\u2013272."},{"key":"B169","series-title":"Intern Med J","first-page":"1759","article-title":"Cytomegalovirus DNAemia and disease: current-era epidemiology, clinical characteristics and outcomes in cancer patients other than allogeneic haemopoietic transplantation","volume":"52","author":"Tay KH","year":"2022","unstructured":"Tay KH, Slavin MA, Thursky KA,  Cytomegalovirus DNAemia and disease: current-era epidemiology, clinical characteristics and outcomes in cancer patients other than allogeneic haemopoietic transplantation. Intern Med J 2022;52:1759\u20131767."},{"key":"B170","series-title":"Cancer Invest","first-page":"488","article-title":"Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome","volume":"23","author":"Montillo M","year":"2005","unstructured":"Montillo M, Schinkoethe T, Elter T. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome. Cancer Invest 2005;23:488\u2013496."},{"key":"B171","series-title":"Clin Lymphoma Myeloma","first-page":"125","article-title":"Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab","volume":"7","author":"O\u2019Brien SM","year":"2006","unstructured":"O\u2019Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 2006;7:125\u2013130."},{"key":"B172","series-title":"Lancet Haematol","first-page":"e127","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo D","year":"2024","unstructured":"Russo D, Schmitt M, Pilorge S,  Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol 2024;11:e127\u2013135."},{"key":"B173","series-title":"Clin Infect Dis","first-page":"618","article-title":"Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients","volume":"28","author":"Nguyen Q","year":"1999","unstructured":"Nguyen Q, Champlin R, Giralt S,  Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis 1999;28:618\u2013623."},{"key":"B174","series-title":"Bone Marrow Transplant","first-page":"175","article-title":"Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study","volume":"22","author":"Moretti S","year":"1998","unstructured":"Moretti S, Zikos P, Van Lint MT,  Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transplant 1998;22:175\u2013180."},{"key":"B175","series-title":"Blood","first-page":"3147","article-title":"How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation","volume":"113","author":"Liang R","year":"2009","unstructured":"Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009;113:3147\u20133153."},{"key":"B176","series-title":"N Engl J Med","first-page":"270","article-title":"Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen","volume":"312","author":"Brechot C","year":"1985","unstructured":"Brechot C, Degos F, Lugassy C,  Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med 1985;312:270\u2013276."},{"key":"B177","series-title":"Transplantation","first-page":"616","article-title":"Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc","volume":"66","author":"Dhedin N","year":"1998","unstructured":"Dhedin N, Douvin C, Kuentz M,  Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998;66:616\u2013619."},{"key":"B178","series-title":"J Viral Hepat","first-page":"807","article-title":"Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and\/or autologous stem cell transplantation for cancer","volume":"17","author":"Borentain P","year":"2010","unstructured":"Borentain P, Colson P, Coso D,  Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and\/or autologous stem cell transplantation for cancer. J Viral Hepat 2010;17:807\u2013815."},{"key":"B179","series-title":"Ann Oncol","first-page":"1170","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports","volume":"22","author":"Evens AM","year":"2011","unstructured":"Evens AM, Jovanovic BD, Su YC,  Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011;22:1170\u20131180."},{"key":"B180","series-title":"Ann Oncol","first-page":"2013","article-title":"Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier","volume":"20","author":"Fukushima N","year":"2009","unstructured":"Fukushima N, Mizuta T, Tanaka M,  Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009;20:2013\u20132017."},{"key":"B181","series-title":"Eur J Haematol","first-page":"243","article-title":"Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative\/HBcAb-positive: a multicenter retrospective study","volume":"85","author":"Ji D","year":"2010","unstructured":"Ji D, Cao J, Hong X,  Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative\/HBcAb-positive: a multicenter retrospective study. Eur J Haematol 2010;85:243\u2013250."},{"key":"B182","series-title":"Cancer","first-page":"115","article-title":"Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy","volume":"116","author":"Koo YX","year":"2010","unstructured":"Koo YX, Tan DS, Tan IB,  Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer 2010;116:115\u2013121."},{"key":"B183","series-title":"Br J Haematol","first-page":"699","article-title":"Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies","volume":"136","author":"Lalazar G","year":"2007","unstructured":"Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007;136:699\u2013712."},{"key":"B184","series-title":"Hepatology","first-page":"702","article-title":"Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation","volume":"36","author":"Lau GKK","year":"2002","unstructured":"Lau GKK, He ML, Fong DYT,  Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002;36:702\u2013709."},{"key":"B185","series-title":"Cancer","first-page":"4769","article-title":"Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma","volume":"116","author":"Matsue K","year":"2010","unstructured":"Matsue K, Kimura S, Takanashi Y,  Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010;116:4769\u20134776."},{"key":"B186","series-title":"J Med Virol","first-page":"299","article-title":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors","volume":"62","author":"Yeo W","year":"2000","unstructured":"Yeo W, Chan PK, Zhong S,  Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299\u2013307."},{"key":"B187","series-title":"J Clin Oncol","first-page":"605","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo W","year":"2009","unstructured":"Yeo W, Chan TC, Leung NW,  Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605\u2013611."},{"key":"B188","series-title":"J Hepatol","first-page":"370","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370\u2013398."},{"key":"B189","series-title":"Hematol Oncol","first-page":"261","article-title":"Hepatitis B infection in patients with lymphomas","volume":"8","author":"Liang RH","year":"1990","unstructured":"Liang RH, Lok AS, Lai CL,  Hepatitis B infection in patients with lymphomas. Hematol Oncol 1990;8:261\u2013270."},{"key":"B190","series-title":"Cancer","first-page":"2927","article-title":"Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients","volume":"92","author":"Dai MS","year":"2001","unstructured":"Dai MS, Lu JJ, Chen YC,  Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients. Cancer 2001;92:2927\u20132932."},{"key":"B191","series-title":"J Med Virol","first-page":"249","article-title":"Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore\/core mutations may play an important role","volume":"60","author":"Steinberg JL","year":"2000","unstructured":"Steinberg JL, Yeo W, Zhong S,  Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore\/core mutations may play an important role. J Med Virol 2000;60:249\u2013255."},{"key":"B192","series-title":"Lancet","first-page":"528","article-title":"Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy","volume":"2","author":"Galbraith RM","year":"1975","unstructured":"Galbraith RM, Eddleston AL, Williams R, Zuckerman AJ. Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975;2:528\u2013530."},{"key":"B193","series-title":"Cancer","first-page":"878","article-title":"Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B","volume":"65","author":"Pinto PC","year":"1990","unstructured":"Pinto PC, Hu E, Bernstein-Singer M,  Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer 1990;65:878\u2013884."},{"key":"B194","series-title":"J Med Virol","first-page":"553","article-title":"Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study","volume":"70","author":"Yeo W","year":"2003","unstructured":"Yeo W, Chan PK, Hui P,  Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 2003;70:553\u2013561."},{"key":"B195","series-title":"Am J Clin Oncol","first-page":"379","article-title":"Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine","volume":"28","author":"Yeo W","year":"2005","unstructured":"Yeo W, Hui EP, Chan AT,  Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol 2005;28:379\u2013384."},{"key":"B196","series-title":"Hematology","first-page":"70","article-title":"Inferior survival and frequent hepatic dysfunction in non-Hodgkin's lymphoma patients with HBV infection: a systematic review and meta-analysis","volume":"27","author":"Zhang MY","year":"2022","unstructured":"Zhang MY, Gao F, Zhao YW,  Inferior survival and frequent hepatic dysfunction in non-Hodgkin's lymphoma patients with HBV infection: a systematic review and meta-analysis. Hematology 2022;27:70\u201379."},{"key":"B197","series-title":"Biol Blood Marrow Transplant","first-page":"1049","article-title":"Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Hammond SP","year":"2009","unstructured":"Hammond SP, Borchelt AM, Ukomadu C,  Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009;15:1049\u20131059."},{"key":"B198","series-title":"Bone Marrow Transplant","first-page":"125","article-title":"Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT","volume":"46","author":"Vigano M","year":"2011","unstructured":"Vigano M, Vener C, Lampertico P,  Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant 2011;46:125\u2013131."},{"key":"B199","series-title":"Haematologica","first-page":"998","article-title":"Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance","volume":"94","author":"Ziakas PD","year":"2009","unstructured":"Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009;94:998\u20131005."},{"key":"B200","series-title":"Cleve Clin J Med","first-page":"S14","article-title":"Hepatitis B treatment: current best practices, avoiding resistance","volume":"76","author":"Gish RG","year":"2009","unstructured":"Gish RG. Hepatitis B treatment: current best practices, avoiding resistance. Cleve Clin J Med 2009;76(Suppl 3):S14\u201319."},{"key":"B201","series-title":"J Clin Virol","first-page":"467","article-title":"Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H","volume":"35","author":"Cortelezzi A","year":"2006","unstructured":"Cortelezzi A, Vigano M, Zilioli VR,  Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J Clin Virol 2006;35:467\u2013469."},{"key":"B202","series-title":"Gastroenterology","first-page":"91","article-title":"Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B","volume":"126","author":"Peters MG","year":"2004","unstructured":"Peters MG, Hann Hw H, Martin P,  Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91\u2013101."},{"key":"B203","series-title":"Int J Clin Pharm","first-page":"1035","article-title":"Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis","volume":"38","author":"Yu S","year":"2016","unstructured":"Yu S, Luo H, Pan M,  Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis. Int J Clin Pharm 2016;38:1035\u20131043."},{"key":"B204","series-title":"J Hepatol","first-page":"533","article-title":"Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection","volume":"62","author":"Agarwal K","year":"2015","unstructured":"Agarwal K, Fung SK, Nguyen TT,  Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol 2015;62:533\u2013540."},{"key":"B205","series-title":"N Engl J Med","first-page":"2442","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin P","year":"2008","unstructured":"Marcellin P, Heathcote EJ, Buti M,  Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442\u20132455."},{"key":"B206","series-title":"Lancet Gastroenterol Hepatol","first-page":"196","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti M","year":"2016","unstructured":"Buti M, Gane E, Seto WK,  Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016;1:196\u2013206."},{"key":"B207","series-title":"Lancet Gastroenterol Hepatol","first-page":"185","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan HL","year":"2016","unstructured":"Chan HL, Fung S, Seto WK,  Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016;1:185\u2013195."},{"key":"B208","series-title":"Expert Rev Gastroenterol Hepatol","first-page":"623","article-title":"Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"17","author":"Liu H","year":"2023","unstructured":"Liu H, Han CL, Tian BW,  Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol 2023;17:623\u2013633."},{"key":"B209","series-title":"Hepatology","first-page":"434","article-title":"No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B","volume":"59","author":"Kitrinos KM","year":"2014","unstructured":"Kitrinos KM, Corsa A, Liu Y,  No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 2014;59:434\u2013442."},{"key":"B210","series-title":"Lancet","first-page":"468","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin P","year":"2013","unstructured":"Marcellin P, Gane E, Buti M,  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013;381:468\u2013475."},{"key":"B211","series-title":"Hepatology","first-page":"72","article-title":"Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir","volume":"49","author":"Leung N","year":"2009","unstructured":"Leung N, Peng CY, Hann HW,  Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009;49:72\u201379."},{"key":"B212","series-title":"Eur J Intern Med","first-page":"333","article-title":"Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients","volume":"21","author":"Watanabe M","year":"2010","unstructured":"Watanabe M, Shibuya A, Takada J,  Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Eur J Intern Med 2010;21:333\u2013337."},{"key":"B213","series-title":"World J Gastroenterol","first-page":"5165","article-title":"Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma","volume":"20","author":"Liu WP","year":"2014","unstructured":"Liu WP, Zheng W, Song YQ,  Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma. World J Gastroenterol 2014;20:5165\u20135170."},{"key":"B214","series-title":"Hepatology","first-page":"1503","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy","volume":"49","author":"Tenney DJ","year":"2009","unstructured":"Tenney DJ, Rose RE, Baldick CJ,  Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503\u20131514."},{"key":"B215","series-title":"Gastroenterology","first-page":"1743","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years","volume":"131","author":"Hadziyannis SJ","year":"2006","unstructured":"Hadziyannis SJ, Tassopoulos NC, Heathcote EJ,  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743\u20131751."},{"key":"B216","series-title":"Gastroenterology","first-page":"132","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","author":"Heathcote EJ","year":"2011","unstructured":"Heathcote EJ, Marcellin P, Buti M,  Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140:132\u2013143."},{"key":"B217","series-title":"Hepatology","first-page":"727","article-title":"Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil","volume":"50","author":"Ha NB","year":"2009","unstructured":"Ha NB, Ha NB, Garcia RT,  Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009;50:727\u2013734."},{"key":"B218","series-title":"Kidney Int","first-page":"1153","article-title":"Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies","volume":"66","author":"Izzedine H","year":"2004","unstructured":"Izzedine H, Hulot JS, Launay-Vacher V,  Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 2004;66:1153\u20131158."},{"key":"B219","series-title":"AIDS","first-page":"1273","article-title":"The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years","volume":"21","author":"Nelson MR","year":"2007","unstructured":"Nelson MR, Katlama C, Montaner JS,  The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007;21:1273\u20131281."},{"key":"B220","series-title":"J Clin Oncol","first-page":"3698","article-title":"Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO Provisional Clinical Opinion update","volume":"38","author":"Hwang JP","year":"2020","unstructured":"Hwang JP, Feld JJ, Hammond SP,  Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO Provisional Clinical Opinion update. J Clin Oncol 2020;38:3698\u20133715."},{"key":"B221","series-title":"Hepatology","first-page":"1560","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault NA","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ,  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67:1560\u20131599."},{"key":"B222","series-title":"Am J Epidemiol","first-page":"484","article-title":"Prevention of perinatal transmission of hepatitis B virus: the sensitivity, specificity, and predictive value of the recommended screening questions to detect high-risk women in an obstetric population","volume":"126","author":"McQuillan GM","year":"1987","unstructured":"McQuillan GM, Townsend TR, Johannes CB,  Prevention of perinatal transmission of hepatitis B virus: the sensitivity, specificity, and predictive value of the recommended screening questions to detect high-risk women in an obstetric population. Am J Epidemiol 1987;126:484\u2013491."},{"key":"B223","article-title":"Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C","author":"Institute of Medicine","unstructured":"Institute of Medicine. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. National Academies Press (US); 2010. Available at: http:\/\/www.cdc.gov\/hepatitis\/pdfs\/iom-hepatitisandlivercancerreport.pdf"},{"key":"B224","series-title":"J Viral Hepat","first-page":"1","article-title":"The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*","volume":"18","author":"Hatzakis A","year":"2011","unstructured":"Hatzakis A, Wait S, Bruix J,  The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat 2011;18(Suppl 1):1\u201316."},{"key":"B225","series-title":"MMWR Recomm Rep","first-page":"1","article-title":"Screening and testing for hepatitis B virus infection: CDC Recommendations - United States, 2023","volume":"72","author":"Conners EE","year":"2023","unstructured":"Conners EE, Panagiotakopoulos L, Hofmeister MG,  Screening and testing for hepatitis B virus infection: CDC Recommendations - United States, 2023. MMWR Recomm Rep 2023;72:1\u201325."},{"key":"B226","series-title":"J Infect Dis","first-page":"469","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study","volume":"206","author":"Lee MH","year":"2012","unstructured":"Lee MH, Yang HI, Lu SN,  Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206:469\u2013477."},{"key":"B227","series-title":"World J Gastroenterol","first-page":"6716","article-title":"Hepatitis C virus reactivation in cancer patients in the era of targeted therapies","volume":"20","author":"Yazici O","year":"2014","unstructured":"Yazici O, Sendur MA, Aksoy S. Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J Gastroenterol 2014;20:6716\u20136724."},{"key":"B228","series-title":"World J Gastroenterol","first-page":"2771","article-title":"Challenges in managing hepatitis C virus infection in cancer patients","volume":"20","author":"Borchardt RA","year":"2014","unstructured":"Borchardt RA, Torres HA. Challenges in managing hepatitis C virus infection in cancer patients. World J Gastroenterol 2014;20:2771\u20132776."},{"key":"B229","article-title":"HCV guidance: recommendations for testing, managing, and treating hepatitis C","author":"AASLD\/IDSA","unstructured":"AASLD\/IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. Accessed November 9, 2017. Available at: www.hcvguidelines.org"},{"key":"B230","article-title":"HIV Surveillance Report","volume":"27","author":"Centers for Disease Control and Prevention","year":"2015","unstructured":"Centers for Disease Control and Prevention. HIV Surveillance Report Vol. 27; 2015. Available at: https:\/\/www.cdc.gov\/hiv\/pdf\/library\/reports\/surveillance\/cdc-hiv-surveillance-report-2015-vol-27.pdf"},{"key":"B231","series-title":"JAMA","first-page":"334","article-title":"Time for oncologists to opt in for routine opt-out HIV testing?","volume":"304","author":"Chiao EY","year":"2010","unstructured":"Chiao EY, Dezube BJ, Krown SE,  Time for oncologists to opt in for routine opt-out HIV testing? JAMA 2010;304:334\u2013339."},{"key":"B232","series-title":"Cancer Epidemiol Biomarkers Prev","first-page":"2551","article-title":"HIV infection, immunodeficiency, viral replication, and the risk of cancer","volume":"20","author":"Silverberg MJ","year":"2011","unstructured":"Silverberg MJ, Chao C, Leyden WA,  HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev 2011;20:2551\u20132559."},{"key":"B233","series-title":"J Natl Cancer Inst","first-page":"753","article-title":"Cancer burden in the HIV-infected population in the United States","volume":"103","author":"Shiels MS","year":"2011","unstructured":"Shiels MS, Pfeiffer RM, Gail MH,  Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011;103:753\u2013762."},{"key":"B234","series-title":"J Acquir Immune Defic Syndr","first-page":"293","article-title":"Survival after cancer diagnosis in persons with AIDS","volume":"39","author":"Biggar RJ","year":"2005","unstructured":"Biggar RJ, Engels EA, Ly S,  Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005;39:293\u2013299."},{"key":"B235","series-title":"Nat Clin Pract Oncol","first-page":"406","article-title":"Therapy insight: AIDS-related malignancies\u2013the influence of antiviral therapy on pathogenesis and management","volume":"2","author":"Yarchoan R","year":"2005","unstructured":"Yarchoan R, Tosato G, Little RF. Therapy insight: AIDS-related malignancies\u2013the influence of antiviral therapy on pathogenesis and management. Nat Clin Pract Oncol 2005;2:406\u2013415."},{"key":"B236","series-title":"Lancet Oncol","first-page":"905","article-title":"Use of antineoplastic agents in patients with cancer who have HIV\/AIDS","volume":"12","author":"Rudek MA","year":"2011","unstructured":"Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV\/AIDS. Lancet Oncol 2011;12:905\u2013912."},{"key":"B237","series-title":"J Oncol Pract","first-page":"384","article-title":"HIV testing in patients with cancer at the initiation of therapy at a large US comprehensive cancer center","volume":"11","author":"Hwang JP","year":"2015","unstructured":"Hwang JP, Granwehr BP, Torres HA,  HIV testing in patients with cancer at the initiation of therapy at a large US comprehensive cancer center. J Oncol Pract 2015;11:384\u2013390."},{"key":"B238","series-title":"MMWR Recomm Rep","first-page":"1","article-title":"Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings","volume":"55","author":"Branson BM","year":"2006","unstructured":"Branson BM, Handsfield HH, Lampe MA,  Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55:1\u201317."},{"key":"B239","series-title":"Ann Pharmacother","first-page":"1125","article-title":"Oral ribavirin for the treatment of noninfluenza respiratory viral infections: a systematic review","volume":"49","author":"Gross AE","year":"2015","unstructured":"Gross AE, Bryson ML. Oral ribavirin for the treatment of noninfluenza respiratory viral infections: a systematic review. Ann Pharmacother 2015;49:1125\u20131135."},{"key":"B240","series-title":"Transpl Infect Dis","first-page":"210","article-title":"Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative","volume":"18","author":"Beaird OE","year":"2016","unstructured":"Beaird OE, Freifeld A, Ison MG,  Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. Transpl Infect Dis 2016;18:210\u2013215."},{"key":"B241","series-title":"Leuk Lymphoma","first-page":"623","article-title":"Serious outbreak of human metapneumovirus in patients with hematologic malignancies","volume":"57","author":"Hoellein A","year":"2016","unstructured":"Hoellein A, Hecker J, Hoffmann D,  Serious outbreak of human metapneumovirus in patients with hematologic malignancies. Leuk Lymphoma 2016;57:623\u2013627."},{"key":"B242","series-title":"J Clin Virol","first-page":"593","article-title":"Human metapneumovirus pneumonia in patients with hematological malignancies","volume":"61","author":"Godet C","year":"2014","unstructured":"Godet C, Le Goff J, Beby-Defaux A,  Human metapneumovirus pneumonia in patients with hematological malignancies. J Clin Virol 2014;61:593\u2013596."},{"key":"B243","series-title":"Cancer Lett","first-page":"358","article-title":"Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: a systematic review","volume":"370","author":"Shah DP","year":"2016","unstructured":"Shah DP, Shah PK, Azzi JM, Chemaly RF. Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: a systematic review. Cancer Lett 2016;370:358\u2013364."},{"key":"B244","series-title":"Pediatr Pulmonol","first-page":"307","article-title":"Respiratory syncytial virus infection outbreak among pediatric patients with oncologic diseases and\/or BMT","volume":"45","author":"Anak S","year":"2010","unstructured":"Anak S, Atay D, Unuvar A,  Respiratory syncytial virus infection outbreak among pediatric patients with oncologic diseases and\/or BMT. Pediatr Pulmonol 2010;45:307\u2013311."},{"key":"B245","series-title":"J Korean Med Sci","first-page":"36","article-title":"Respiratory viral infections after hematopoietic stem cell transplantation in children","volume":"28","author":"Choi JH","year":"2013","unstructured":"Choi JH, Choi EH, Kang HJ,  Respiratory viral infections after hematopoietic stem cell transplantation in children. J Korean Med Sci 2013;28:36\u201341."},{"key":"B246","series-title":"Clin Infect Dis","first-page":"402","article-title":"Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature","volume":"46","author":"Khanna N","year":"2008","unstructured":"Khanna N, Widmer AF, Decker M,  Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis 2008;46:402\u2013412."},{"key":"B247","series-title":"Pediatr Infect Dis J","first-page":"1073","article-title":"Risk factors and outcomes for respiratory syncytial virus-related infections in immunocompromised children","volume":"32","author":"Asner S","year":"2013","unstructured":"Asner S, Stephens D, Pedulla P,  Risk factors and outcomes for respiratory syncytial virus-related infections in immunocompromised children. Pediatr Infect Dis J 2013;32:1073\u20131076."},{"key":"B248","series-title":"Pediatr Transplant","first-page":"133","article-title":"The impact of RSV, adenovirus, influenza, and parainfluenza infection in pediatric patients receiving stem cell transplant, solid organ transplant, or cancer chemotherapy","volume":"17","author":"Lo MS","year":"2013","unstructured":"Lo MS, Lee GM, Gunawardane N,  The impact of RSV, adenovirus, influenza, and parainfluenza infection in pediatric patients receiving stem cell transplant, solid organ transplant, or cancer chemotherapy. Pediatr Transplant 2013;17:133\u2013143."},{"key":"B249","series-title":"Bone Marrow Transplant","first-page":"393","article-title":"Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients","volume":"16","author":"Whimbey E","year":"1995","unstructured":"Whimbey E, Champlin RE, Englund JA,  Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995;16:393\u2013399."},{"key":"B250","series-title":"Transpl Infect Dis","first-page":"242","article-title":"Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients","volume":"16","author":"Marcelin JR","year":"2014","unstructured":"Marcelin JR, Wilson JW, Razonable RR, Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transpl Infect Dis 2014;16:242\u2013250."},{"key":"B251","series-title":"Clin Microbiol Infect","first-page":"1272","article-title":"Ribavirin treatment for respiratory syncytial virus infection in patients with haematologic malignancy and haematopoietic stem cell transplant recipients: a systematic review and meta-analysis","volume":"29","author":"Manothummetha K","year":"2023","unstructured":"Manothummetha K, Mongkolkaew T, Tovichayathamrong P,  Ribavirin treatment for respiratory syncytial virus infection in patients with haematologic malignancy and haematopoietic stem cell transplant recipients: a systematic review and meta-analysis. Clin Microbiol Infect 2023;29:1272\u20131279."},{"key":"B252","series-title":"MMWR Recomm Rep","first-page":"1","article-title":"Antiviral agents for the treatment and chemoprophylaxis of influenza","volume":"60","year":"2011","unstructured":"Centers for Disease Control and Prevention. Antiviral agents for the treatment and chemoprophylaxis of influenza. MMWR Recomm Rep 2011;60:1\u201326."},{"key":"B253","series-title":"MMWR Recomm Rep","first-page":"1","article-title":"Antiviral agents for the treatment and chemoprophylaxis of influenza \u2013 recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"Fiore AE","year":"2011","unstructured":"Fiore AE, Fry A, Shay D,  Antiviral agents for the treatment and chemoprophylaxis of influenza \u2013 recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60:1\u201324."},{"key":"B254","series-title":"Clin Infect Dis","first-page":"27","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell LA","year":"2007","unstructured":"Mandell LA, Wunderink RG, Anzueto A,  Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:27\u201372."},{"key":"B255","article-title":"Influenza (flu) antiviral drugs and related information","author":"U.S. Food and Drug Administration","unstructured":"U.S. Food and Drug Administration. Influenza (flu) antiviral drugs and related information. Accessed November 9, 2017. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/InformationbyDrugClass\/ucm100228.htm"},{"key":"B256","series-title":"Antivir Ther","first-page":"651","article-title":"A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults","volume":"18","author":"Ison MG","year":"2013","unstructured":"Ison MG, Hui DS, Clezy K,  A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. Antivir Ther 2013;18:651\u2013661."},{"key":"B257","series-title":"Open Forum Infect Dis","first-page":"ofaa562","article-title":"Clinical effectiveness of intravenous peramivir compared with oseltamivir in patients with severe influenza A with primary viral pneumonia: a randomized controlled study","volume":"8","author":"Chen HD","year":"2021","unstructured":"Chen HD, Wang X, Yu SL,  Clinical effectiveness of intravenous peramivir compared with oseltamivir in patients with severe influenza A with primary viral pneumonia: a randomized controlled study. Open Forum Infect Dis 2021;8:ofaa562."},{"key":"B258","series-title":"Transpl Infect Dis","first-page":"e13542","article-title":"Baloxavir treatment of oseltamivir-resistant influenza A\/H1pdm09 in two immunocompromised patients","volume":"23","author":"Macesic N","year":"2021","unstructured":"Macesic N, Laplante JM, Aaron JG,  Baloxavir treatment of oseltamivir-resistant influenza A\/H1pdm09 in two immunocompromised patients. Transpl Infect Dis 2021;23:e13542."},{"key":"B259","series-title":"BMC Infect Dis","first-page":"478","article-title":"Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A\/H3N2 with a dual E119D\/R292K substitution after allogeneic hematopoietic cell transplantation: a case report","volume":"20","author":"Harada N","year":"2020","unstructured":"Harada N, Shibata W, Koh H,  Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A\/H3N2 with a dual E119D\/R292K substitution after allogeneic hematopoietic cell transplantation: a case report. BMC Infect Dis 2020;20:478."},{"key":"B260","series-title":"Transpl Infect Dis","first-page":"e13336","article-title":"Baloxavir for the treatment of influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir","volume":"22","author":"Salvatore M","year":"2020","unstructured":"Salvatore M, Laplante JM, Soave R,  Baloxavir for the treatment of influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir. Transpl Infect Dis 2020;22:e13336."},{"key":"B261","series-title":"Lancet Infect Dis","first-page":"1204","article-title":"Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Ison MG","year":"2020","unstructured":"Ison MG, Portsmouth S, Yoshida Y,  Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis 2020;20:1204\u20131214."},{"key":"B262","series-title":"Biol Blood Marrow Transplant","first-page":"1589","article-title":"Evaluation and management of BK virus-associated nephropathy following allogeneic hematopoietic cell transplantation","volume":"17","author":"Raval M","year":"2011","unstructured":"Raval M, Gulbis A, Bollard C,  Evaluation and management of BK virus-associated nephropathy following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011;17:1589\u20131593."},{"key":"B263","series-title":"Bone Marrow Transplant","first-page":"664","article-title":"High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"49","author":"Gilis L","year":"2014","unstructured":"Gilis L, Morisset S, Billaud G,  High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2014;49:664\u2013670."},{"key":"B264","series-title":"Biol Blood Marrow Transplant","first-page":"723","article-title":"Cidofovir in the treatment of BK virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation","volume":"22","author":"Philippe M","year":"2016","unstructured":"Philippe M, Ranchon F, Gilis L,  Cidofovir in the treatment of BK virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2016;22:723\u2013730."},{"key":"B265","series-title":"Bone Marrow Transplant","first-page":"1302","article-title":"An expert consensus on prevention, diagnosis, and management of hemorrhagic cystitis in pediatric hematopoietic cell transplantation, on behalf of the Infectious Disease and Hematopoietic Cell Transplant Working groups of Italian Pediatric Hematology Oncology Association (AIEOP)","volume":"59","author":"Dell'Orso G","year":"2024","unstructured":"Dell'Orso G, Carlucci M, Cesaro S,  An expert consensus on prevention, diagnosis, and management of hemorrhagic cystitis in pediatric hematopoietic cell transplantation, on behalf of the Infectious Disease and Hematopoietic Cell Transplant Working groups of Italian Pediatric Hematology Oncology Association (AIEOP). Bone Marrow Transplant 2024;59:1302\u20131308."},{"key":"B266","series-title":"Mayo Clin Proc","first-page":"1052","article-title":"Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials","volume":"82","author":"Green H","year":"2007","unstructured":"Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007;82:1052\u20131059."},{"key":"B267","series-title":"N Engl J Med","first-page":"1419","article-title":"Successful chemoprophylaxis for Pneumocystis carinii pneumonitis","volume":"297","author":"Hughes WT","year":"1977","unstructured":"Hughes WT, Kuhn S, Chaudhary S,  Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1977;297:1419\u20131426."},{"key":"B268","series-title":"N Engl J Med","first-page":"1627","article-title":"Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis","volume":"316","author":"Hughes WT","year":"1987","unstructured":"Hughes WT, Rivera GK, Schell MJ,  Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 1987;316:1627\u20131632."},{"key":"B269","series-title":"Pediatrics","first-page":"e47","article-title":"Successful intermittent prophylaxis with trimethoprim\/sulfamethoxazole 2 days per week for Pneumocystis carinii (jiroveci) pneumonia in pediatric oncology patients","volume":"120","author":"Lindemulder S","year":"2007","unstructured":"Lindemulder S, Albano E. Successful intermittent prophylaxis with trimethoprim\/sulfamethoxazole 2 days per week for Pneumocystis carinii (jiroveci) pneumonia in pediatric oncology patients. Pediatrics 2007;120:e47\u201351."},{"key":"B270","series-title":"Bone Marrow Transplant","first-page":"483","article-title":"Fungal infection prevention after hematopoietic cell transplantation","volume":"44","author":"Marr KA","year":"2009","unstructured":"Marr KA, Bow E, Chiller T,  Fungal infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009;44:483\u2013487."},{"key":"B271","series-title":"Pediatr Infect Dis J","first-page":"933","article-title":"Intravenous pentamidine is safe and effective as primary pneumocystis pneumonia prophylaxis in children and adolescents undergoing hematopoietic stem cell transplantation","volume":"32","author":"DeMasi JM","year":"2013","unstructured":"DeMasi JM, Cox JA, Leonard D,  Intravenous pentamidine is safe and effective as primary pneumocystis pneumonia prophylaxis in children and adolescents undergoing hematopoietic stem cell transplantation. Pediatr Infect Dis J 2013;32:933\u2013936."},{"key":"B272","series-title":"Transpl Infect Dis","first-page":"63","article-title":"Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation","volume":"18","author":"Diri R","year":"2016","unstructured":"Diri R, Anwer F, Yeager A,  Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2016;18:63\u201369."},{"key":"B273","series-title":"Pediatr Blood Cancer","first-page":"779","article-title":"Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients","volume":"50","author":"Kim SY","year":"2008","unstructured":"Kim SY, Dabb AA, Glenn DJ,  Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients. Pediatr Blood Cancer 2008;50:779\u2013783."},{"key":"B274","series-title":"Biol Blood Marrow Transplant","first-page":"241","article-title":"Dapsone-induced methemoglobinemia after hematopoietic stem cell transplantation","volume":"12","author":"Dunford LM","year":"2006","unstructured":"Dunford LM, Roy DM, Hahn TE,  Dapsone-induced methemoglobinemia after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12:241\u2013242."},{"key":"B275","series-title":"N Engl J Med","first-page":"1889","article-title":"Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group","volume":"339","author":"El-Sadr WM","year":"1998","unstructured":"El-Sadr WM, Murphy RL, Yurik TM,  Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med 1998;339:1889\u20131895."},{"key":"B276","series-title":"Cancer","first-page":"1654","article-title":"Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia","volume":"109","author":"Madden RM","year":"2007","unstructured":"Madden RM, Pui CH, Hughes WT,  Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia. Cancer 2007;109:1654\u20131658."},{"key":"B277","series-title":"N Engl J Med","first-page":"661","article-title":"Pneumocystis carinii pneumonia developing within one month of intensive chemotherapy for treatment of acute lymphoblastic leukemia","volume":"325","author":"Kritz A","year":"1991","unstructured":"Kritz A, Sepkowitz K, Weiss M,  Pneumocystis carinii pneumonia developing within one month of intensive chemotherapy for treatment of acute lymphoblastic leukemia. N Engl J Med 1991;325:661\u2013662."},{"key":"B278","series-title":"Clin Infect Dis","first-page":"S416","article-title":"Pneumocystis carinii pneumonia in patients without AIDS","volume":"17","author":"Sepkowitz KA","year":"1993","unstructured":"Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 1993;17(Suppl 2):S416\u2013422."},{"key":"B279","series-title":"Semin Respir Infect","first-page":"114","article-title":"Pneumocystis carinii pneumonia among patients with neoplastic disease","volume":"7","author":"Sepkowitz KA","year":"1992","unstructured":"Sepkowitz KA. Pneumocystis carinii pneumonia among patients with neoplastic disease. Semin Respir Infect 1992;7:114\u2013121."},{"key":"B280","series-title":"JAMA","first-page":"832","article-title":"Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital","volume":"267","author":"Sepkowitz KA","year":"1992","unstructured":"Sepkowitz KA, Brown AE, Telzak EE,  Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992;267:832\u2013837."},{"key":"B281","series-title":"BMJ Open","first-page":"e068943","article-title":"Prophylaxis for Pneumocystis carinii pneumonia in non-Hodgkin's lymphoma undergoing R-CHOP21 in China: a meta-analysis and cost-effectiveness analysis","volume":"13","author":"Huang X","year":"2023","unstructured":"Huang X, Huang X, Lin S,  Prophylaxis for Pneumocystis carinii pneumonia in non-Hodgkin's lymphoma undergoing R-CHOP21 in China: a meta-analysis and cost-effectiveness analysis. BMJ Open 2023;13:e068943."},{"key":"B282","series-title":"Am J Med","first-page":"27","article-title":"Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience","volume":"102","author":"Bowden RA","year":"1997","unstructured":"Bowden RA. Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience. Am J Med 1997;102:27\u201330."},{"key":"B283","series-title":"Biol Blood Marrow Transplant","first-page":"5S","article-title":"Respiratory virus infections in stem cell transplant patients: the European experience","volume":"7","author":"Ljungman P","year":"2001","unstructured":"Ljungman P. Respiratory virus infections in stem cell transplant patients: the European experience. Biol Blood Marrow Transplant 2001;7(Suppl):5S\u20137S."},{"key":"B284","series-title":"Clin Infect Dis","first-page":"778","article-title":"Community respiratory virus infections among hospitalized adult bone marrow transplant recipients","volume":"22","author":"Whimbey E","year":"1996","unstructured":"Whimbey E, Champlin RE, Couch RB,  Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996;22:778\u2013782."},{"key":"B285","series-title":"Cancer","first-page":"350","article-title":"Influenza in children and young adults with cancer: 20 cases","volume":"39","author":"Feldman S","year":"1977","unstructured":"Feldman S, Webster RG, Sugg M. Influenza in children and young adults with cancer: 20 cases. Cancer 1977;39:350\u2013353."},{"key":"B286","series-title":"J Pediatr","first-page":"33","article-title":"Influenza in children with cancer","volume":"115","author":"Kempe A","year":"1989","unstructured":"Kempe A, Hall CB, MacDonald NE,  Influenza in children with cancer. J Pediatr 1989;115:33\u201339."},{"key":"B287","series-title":"Support Care Cancer","first-page":"198","article-title":"Epidemiology of influenza A virus infection in patients with acute or chronic leukemia","volume":"3","author":"Elting LS","year":"1995","unstructured":"Elting LS, Whimbey E, Lo W,  Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Support Care Cancer 1995;3:198\u2013202."},{"key":"B288","series-title":"MMWR Recomm Rep","first-page":"1","article-title":"Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"Fiore AE","year":"2010","unstructured":"Fiore AE, Fry A, Shay D,  Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010;60:1\u201324."},{"key":"B289","series-title":"Cancer","first-page":"841","article-title":"Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles","volume":"123","author":"Keam B","year":"2017","unstructured":"Keam B, Kim MK, Choi Y,  Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles. Cancer 2017;123:841\u2013848."},{"key":"B290","series-title":"MMWR Recomm Rep","first-page":"1","article-title":"Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"52","author":"Harper SA","year":"2003","unstructured":"Harper SA, Fukuda K, Cox NJ, Bridges CB. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003;52:1\u20138."},{"key":"B291","series-title":"Vaccine","first-page":"3141","article-title":"Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection","volume":"34","author":"Hakim H","year":"2016","unstructured":"Hakim H, Allison KJ, Van de Velde LA,  Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection. Vaccine 2016;34:3141\u20133148."},{"key":"B292","series-title":"Vaccine","first-page":"630","article-title":"Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: a pilot randomized clinical trial","volume":"34","author":"Jamshed S","year":"2016","unstructured":"Jamshed S, Walsh EE, Dimitroff LJ,  Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: a pilot randomized clinical trial. Vaccine 2016;34:630\u2013635."},{"key":"B293","series-title":"Clin Infect Dis","first-page":"e4269","article-title":"A randomized trial of two 2-dose influenza vaccination strategies for patients following autologous hematopoietic stem cell transplantation","volume":"73","author":"Teh BW","year":"2021","unstructured":"Teh BW, Leung VKY, Mordant FL,  A randomized trial of two 2-dose influenza vaccination strategies for patients following autologous hematopoietic stem cell transplantation. Clin Infect Dis 2021;73:e4269\u20134277."},{"key":"B294","series-title":"Clin Infect Dis","first-page":"1102","article-title":"A phase 3, randomized, double-blind, comparator-controlled study to evaluate safety, tolerability, and immunogenicity of V114, A 15-valent pneumococcal conjugate vaccine, in allogeneic hematopoietic cell transplant recipients (PNEU-STEM)","volume":"77","author":"Wilck M","year":"2023","unstructured":"Wilck M, Cornely OA, Cordonnier C,  A phase 3, randomized, double-blind, comparator-controlled study to evaluate safety, tolerability, and immunogenicity of V114, A 15-valent pneumococcal conjugate vaccine, in allogeneic hematopoietic cell transplant recipients (PNEU-STEM). Clin Infect Dis 2023;77:1102\u20131110."},{"key":"B295","series-title":"Br J Haematol","first-page":"308","article-title":"Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology task force","volume":"155","author":"Davies JM","year":"2011","unstructured":"Davies JM, Lewis MP, Wimperis J,  Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology task force. Br J Haematol 2011;155:308\u2013317."},{"key":"B296","series-title":"Hematology Am Soc Hematol Educ Program","first-page":"328","article-title":"Preventing infections in children and adults with asplenia","volume":"2020","author":"Lee GM","year":"2020","unstructured":"Lee GM. Preventing infections in children and adults with asplenia. Hematology Am Soc Hematol Educ Program 2020;2020:328\u2013335."},{"key":"B297","series-title":"MMWR Recomm Rep","first-page":"1","article-title":"General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"55","author":"Kroger AT","year":"2006","unstructured":"Kroger AT, Atkinson WL, Marcuse EK, Pickering LK. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55:1\u201348."},{"key":"B298","series-title":"Ann Intern Med","first-page":"552","article-title":"Influenza immunization of adult patients with malignant diseases","volume":"87","author":"Ortbals DW","year":"1977","unstructured":"Ortbals DW, Liebhaber H, Presant CA,  Influenza immunization of adult patients with malignant diseases. Ann Intern Med 1977;87:552\u2013557."},{"key":"B299","series-title":"J Oncol Pharm Pract","first-page":"143","article-title":"Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppressive chemotherapy","volume":"12","author":"Sommer AL","year":"2006","unstructured":"Sommer AL, Wachel BK, Smith JA. Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppressive chemotherapy. J Oncol Pharm Pract 2006;12:143\u2013154."},{"key":"B300","series-title":"Biol Blood Marrow Transplant","first-page":"1143","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn M","year":"2009","unstructured":"Tomblyn M, Chiller T, Einsele H,  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:1143\u20131238."},{"key":"B301","series-title":"Infect Control Hosp Epidemiol","first-page":"525","article-title":"Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised patients with hematologic malignancies","volume":"23","author":"Hahn T","year":"2002","unstructured":"Hahn T, Cummings KM, Michalek AM,  Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised patients with hematologic malignancies. Infect Control Hosp Epidemiol 2002;23:525\u2013531."},{"key":"B302","series-title":"Sci Rep","first-page":"11789","article-title":"The influence of high-efficiency particulate air filtration on mortality among multiple myeloma patients receiving autologous stem cell transplantation","volume":"11","author":"Tsai CK","year":"2021","unstructured":"Tsai CK, Yeh CM, Hong YC,  The influence of high-efficiency particulate air filtration on mortality among multiple myeloma patients receiving autologous stem cell transplantation. Sci Rep 2021;11:11789."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/9\/article-p617.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/9\/article-p617.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/9\/article-p617.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T08:34:31Z","timestamp":1731486871000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/9\/article-p617.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":302,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2024.0056","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}